Peginterferon and Lamivudine for Hepatitis B
To the Editor: Marcellin and colleagues (Sept. 16 issue) 1 report that patients with hepatitis B e antigen (HBeAg)–negative chronic hepatitis B had higher rates of a sustained response to treatment with peginterferon alfa-2a than with lamivudine. 1 HBeAg-negative chronic hepatitis B is usually assoc...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 2004-12, Vol.351 (27), p.2879-2879 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2879 |
|---|---|
| container_issue | 27 |
| container_start_page | 2879 |
| container_title | The New England journal of medicine |
| container_volume | 351 |
| creator | Assy, N Nimer Hussein, Osamah |
| description | To the Editor:
Marcellin and colleagues (Sept. 16 issue)
1
report that patients with hepatitis B e antigen (HBeAg)–negative chronic hepatitis B had higher rates of a sustained response to treatment with peginterferon alfa-2a than with lamivudine.
1
HBeAg-negative chronic hepatitis B is usually associated with precore mutations,
2
but it may also develop in patients infected with wild-type strains, with mutations in the basic core promoter.
3
Whether these two groups of patients with HBeAg-negative chronic hepatitis differ in their responses to therapy is not known. The study by Marcellin et al. would have been more informative if hepatitis B virus (HBV) genome . . . |
| doi_str_mv | 10.1056/NEJM200412303512720 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67197744</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67197744</sourcerecordid><originalsourceid>FETCH-LOGICAL-c328t-cbfd58b74d9b115d93cdb498139ee48219f3f14f2a35ae86f083a5aa752270b93</originalsourceid><addsrcrecordid>eNp9kDtPwzAURi0EoqXwC5BQJhYI-BnbI60KBZXHALPlxNcoVZ0UO0Hi3xPUSiyIu9zlfGc4CJ0SfEWwKK6f5g-PFGNOKMNMECop3kNjIhjLOcfFPhpjTFXOpWYjdJTSCg9HuD5EIyIKKhjnY3T5Au9100H0ENsms43LljbUn72rG8h8G7MFbGxXd3XKpsfowNt1gpPdn6C32_nrbJEvn-_uZzfLvGJUdXlVeidUKbnTJSHCaVa5kmtFmAbgihLtmSfcU8uEBVV4rJgV1kpBqcSlZhN0vvVuYvvRQ-pMqFMF67VtoO2TKSTRUnI-gGwLVrFNKYI3m1gHG78MweYnkvkj0rA62-n7MoD73eyqDMDFFgghmQZW4V_dN9OnbFU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67197744</pqid></control><display><type>article</type><title>Peginterferon and Lamivudine for Hepatitis B</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>New England Journal of Medicine</source><creator>Assy, N Nimer ; Hussein, Osamah</creator><creatorcontrib>Assy, N Nimer ; Hussein, Osamah</creatorcontrib><description>To the Editor:
Marcellin and colleagues (Sept. 16 issue)
1
report that patients with hepatitis B e antigen (HBeAg)–negative chronic hepatitis B had higher rates of a sustained response to treatment with peginterferon alfa-2a than with lamivudine.
1
HBeAg-negative chronic hepatitis B is usually associated with precore mutations,
2
but it may also develop in patients infected with wild-type strains, with mutations in the basic core promoter.
3
Whether these two groups of patients with HBeAg-negative chronic hepatitis differ in their responses to therapy is not known. The study by Marcellin et al. would have been more informative if hepatitis B virus (HBV) genome . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJM200412303512720</identifier><identifier>PMID: 15625344</identifier><language>eng</language><publisher>United States: Massachusetts Medical Society</publisher><subject>Antiviral Agents - therapeutic use ; DNA, Viral - blood ; Drug Resistance, Viral ; Drug Therapy, Combination ; Genome, Viral ; Hepatitis B e Antigens - blood ; Hepatitis B virus - genetics ; Hepatitis B, Chronic - drug therapy ; Hepatitis B, Chronic - immunology ; Hepatitis B, Chronic - virology ; Humans ; Interferon-alpha - therapeutic use ; Lamivudine - therapeutic use ; Mutation ; Polyethylene Glycols - therapeutic use ; Recombinant Proteins</subject><ispartof>The New England journal of medicine, 2004-12, Vol.351 (27), p.2879-2879</ispartof><rights>Copyright © 2004 Massachusetts Medical Society. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c328t-cbfd58b74d9b115d93cdb498139ee48219f3f14f2a35ae86f083a5aa752270b93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJM200412303512720$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.nejm.org/doi/full/10.1056/NEJM200412303512720$$EHTML$$P50$$Gmms$$H</linktohtml><link.rule.ids>314,776,780,2746,2747,26080,27901,27902,52357,54039</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15625344$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Assy, N Nimer</creatorcontrib><creatorcontrib>Hussein, Osamah</creatorcontrib><title>Peginterferon and Lamivudine for Hepatitis B</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>To the Editor:
Marcellin and colleagues (Sept. 16 issue)
1
report that patients with hepatitis B e antigen (HBeAg)–negative chronic hepatitis B had higher rates of a sustained response to treatment with peginterferon alfa-2a than with lamivudine.
1
HBeAg-negative chronic hepatitis B is usually associated with precore mutations,
2
but it may also develop in patients infected with wild-type strains, with mutations in the basic core promoter.
3
Whether these two groups of patients with HBeAg-negative chronic hepatitis differ in their responses to therapy is not known. The study by Marcellin et al. would have been more informative if hepatitis B virus (HBV) genome . . .</description><subject>Antiviral Agents - therapeutic use</subject><subject>DNA, Viral - blood</subject><subject>Drug Resistance, Viral</subject><subject>Drug Therapy, Combination</subject><subject>Genome, Viral</subject><subject>Hepatitis B e Antigens - blood</subject><subject>Hepatitis B virus - genetics</subject><subject>Hepatitis B, Chronic - drug therapy</subject><subject>Hepatitis B, Chronic - immunology</subject><subject>Hepatitis B, Chronic - virology</subject><subject>Humans</subject><subject>Interferon-alpha - therapeutic use</subject><subject>Lamivudine - therapeutic use</subject><subject>Mutation</subject><subject>Polyethylene Glycols - therapeutic use</subject><subject>Recombinant Proteins</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kDtPwzAURi0EoqXwC5BQJhYI-BnbI60KBZXHALPlxNcoVZ0UO0Hi3xPUSiyIu9zlfGc4CJ0SfEWwKK6f5g-PFGNOKMNMECop3kNjIhjLOcfFPhpjTFXOpWYjdJTSCg9HuD5EIyIKKhjnY3T5Au9100H0ENsms43LljbUn72rG8h8G7MFbGxXd3XKpsfowNt1gpPdn6C32_nrbJEvn-_uZzfLvGJUdXlVeidUKbnTJSHCaVa5kmtFmAbgihLtmSfcU8uEBVV4rJgV1kpBqcSlZhN0vvVuYvvRQ-pMqFMF67VtoO2TKSTRUnI-gGwLVrFNKYI3m1gHG78MweYnkvkj0rA62-n7MoD73eyqDMDFFgghmQZW4V_dN9OnbFU</recordid><startdate>20041230</startdate><enddate>20041230</enddate><creator>Assy, N Nimer</creator><creator>Hussein, Osamah</creator><general>Massachusetts Medical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20041230</creationdate><title>Peginterferon and Lamivudine for Hepatitis B</title><author>Assy, N Nimer ; Hussein, Osamah</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c328t-cbfd58b74d9b115d93cdb498139ee48219f3f14f2a35ae86f083a5aa752270b93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Antiviral Agents - therapeutic use</topic><topic>DNA, Viral - blood</topic><topic>Drug Resistance, Viral</topic><topic>Drug Therapy, Combination</topic><topic>Genome, Viral</topic><topic>Hepatitis B e Antigens - blood</topic><topic>Hepatitis B virus - genetics</topic><topic>Hepatitis B, Chronic - drug therapy</topic><topic>Hepatitis B, Chronic - immunology</topic><topic>Hepatitis B, Chronic - virology</topic><topic>Humans</topic><topic>Interferon-alpha - therapeutic use</topic><topic>Lamivudine - therapeutic use</topic><topic>Mutation</topic><topic>Polyethylene Glycols - therapeutic use</topic><topic>Recombinant Proteins</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Assy, N Nimer</creatorcontrib><creatorcontrib>Hussein, Osamah</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Assy, N Nimer</au><au>Hussein, Osamah</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Peginterferon and Lamivudine for Hepatitis B</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>2004-12-30</date><risdate>2004</risdate><volume>351</volume><issue>27</issue><spage>2879</spage><epage>2879</epage><pages>2879-2879</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><abstract>To the Editor:
Marcellin and colleagues (Sept. 16 issue)
1
report that patients with hepatitis B e antigen (HBeAg)–negative chronic hepatitis B had higher rates of a sustained response to treatment with peginterferon alfa-2a than with lamivudine.
1
HBeAg-negative chronic hepatitis B is usually associated with precore mutations,
2
but it may also develop in patients infected with wild-type strains, with mutations in the basic core promoter.
3
Whether these two groups of patients with HBeAg-negative chronic hepatitis differ in their responses to therapy is not known. The study by Marcellin et al. would have been more informative if hepatitis B virus (HBV) genome . . .</abstract><cop>United States</cop><pub>Massachusetts Medical Society</pub><pmid>15625344</pmid><doi>10.1056/NEJM200412303512720</doi><tpages>1</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 2004-12, Vol.351 (27), p.2879-2879 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67197744 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; New England Journal of Medicine |
| subjects | Antiviral Agents - therapeutic use DNA, Viral - blood Drug Resistance, Viral Drug Therapy, Combination Genome, Viral Hepatitis B e Antigens - blood Hepatitis B virus - genetics Hepatitis B, Chronic - drug therapy Hepatitis B, Chronic - immunology Hepatitis B, Chronic - virology Humans Interferon-alpha - therapeutic use Lamivudine - therapeutic use Mutation Polyethylene Glycols - therapeutic use Recombinant Proteins |
| title | Peginterferon and Lamivudine for Hepatitis B |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T22%3A00%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Peginterferon%20and%20Lamivudine%20for%20Hepatitis%20B&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Assy,%20N%20Nimer&rft.date=2004-12-30&rft.volume=351&rft.issue=27&rft.spage=2879&rft.epage=2879&rft.pages=2879-2879&rft.issn=0028-4793&rft.eissn=1533-4406&rft_id=info:doi/10.1056/NEJM200412303512720&rft_dat=%3Cproquest_cross%3E67197744%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=67197744&rft_id=info:pmid/15625344&rfr_iscdi=true |